Instantaneous healthcare backed by 5G to drive the Rheumatoid Arthritis Treatment Market at a CAGR of 5.7%

The global revenue from the rheumatoid arthritis treatment market stands at US$ 42.9 Bn in 2022, with the global market expected to grow at a CAGR of 5.7% to reach a valuation of approximately US$ 79.1 Bn by the end of 2033.

As assessed by Persistence Market Research, disease modifying anti-rheumatic drug (DMARD) therapy holds a market share of around 88.3% in 2022. Overall, rheumatoid arthritis treatment market sales account for approximately 43.1% revenue share in the global anti-inflammatory therapeutics market, which was valued at around US$ 99.6 Bn in 2022.

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects the joints and causes inflammation and pain. The disease can also cause damage to other organs in the body. The rheumatoid arthritis treatment market has witnessed significant growth in recent years, driven by the increasing prevalence of the disease and the development of novel therapies.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22555

The global rheumatoid arthritis treatment market is estimated to be valued at US$ 40.5 Bn in 2021, and is expected to exhibit a CAGR of around 6% over the forecast period (2021 - 2031).

Key Take aways from Market Study

Under therapy, DMARDs hold maximum value share, owing to increasing awareness associated with their utilization.

By distribution channel, hospital pharmacies hold a notable revenue share of more than 75% in the market.

The market North America accounted for a share of over 40% in 2020, and is expected to experience significant growth over the next ten years.
Europe is the next dominating region with a market share of 28% in 2020, due to well-developed healthcare infrastructure largely supported by the government.

"Rise in prevalence of rheumatoid arthritis along with increase in adoption of DMARD therapies, flourishing combination treatment, and supportive government policies are expected to drive market growth," says a Persistence Market Research analyst.

Get To Touch in our Expert @ https://www.persistencemarketresearch.com/ask-an-expert/22555

Collaborations and Acquisitions - Imperative Strategy for Market Players

Major companies in the rheumatoid arthritis treatment market are actively engaging in acquisitions and expansions in order to enhance their product portfolios and outreach to a large number of customers. Globally, leading companies are acquiring other companies who are facing a large number of product recalls in the market.

In April 2021, Novartis signed an initial agreement with Roche to reserve capacity and implement technology transfer for the production of active pharmaceutical ingredient (API) for Roche's Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid arthritis, which is also being tested in various clinical trials investigating the safety and efficacy in COVID-19-associated pneumonia.

In October 2020, Johnson & Johnson announced the successful acquisition of Momenta Pharmaceuticals, Inc. ("Momenta"), a company that discovered and developed novel therapies for immune-mediated diseases.

COVID-19 Crisis Impact

Due to the unprecedented pandemic scenario, the healthcare sector has been the central point across regions. As import activities were halted, this adversely affected the finances of a majority of healthcare companies. Every industry, including healthcare, is suffering from supply chain disruptions.

The World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international significance on January 30, 2020. Around 210 countries have been affected by COVID-19. Patients with rheumatoid arthritis who contract COVID-19 infection, according to the Lancet Rheumatology 2020, are at a high risk of experiencing serious symptoms and complications.

Some DMARDs commonly used to treat rheumatoid arthritis, such as hydroxychloroquine drugs, are being investigated as potential therapy for COVID-19. Moreover, other generally used therapies such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra) are being assessed in patients with COVID-19. Thus, COVID-19 infection uplifted growth opportunities for manufacturers of rheumatoid arthritis drugs. For instance,

Tocilizumab, a drug originally used for rheumatoid arthritis, is seeing increased use in treating severe COVID-19 patients.

A drug developed for rheumatoid arthritis by global pharma company Roche is licensed exclusively to Indian pharma company Cipla.

If You Want To Know The Business Opportunity/Market Value, Purchase The Premium Insight @ https://www.persistencemarketresearch.com/checkout/22555

Related Reports:

Sleep Aids Market:
https://www.persistencemarketresearch.com/market-research/sleep-aids-market.asp

Global Biological Drugs Market:
https://www.persistencemarketresearch.com/market-research/global-biological-drugs-market.asp

Home Infusion Therapy Market:
https://www.persistencemarketresearch.com/market-research/home-infusion-therapy-market.asp

Obesity Surgery Devices Market:
https://www.persistencemarketresearch.com/market-research/obesity-surgery-devices-market.asp

Contact us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

This release was published on openPR.